National Planning Corp lifted its position in Eli Lilly and Company (NYSE:LLY) by 8.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,478 shares of the company’s stock after purchasing an additional 737 shares during the quarter. National Planning Corp’s holdings in Eli Lilly and were worth $784,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. BlackRock Inc. grew its position in Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after acquiring an additional 59,978,664 shares in the last quarter. Vanguard Group Inc. grew its position in Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after acquiring an additional 2,181,701 shares in the last quarter. Winslow Capital Management LLC grew its position in Eli Lilly and by 79.7% in the first quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock worth $326,008,000 after acquiring an additional 1,719,538 shares in the last quarter. Harbour Capital Advisors LLC grew its position in Eli Lilly and by 7,919.1% in the second quarter. Harbour Capital Advisors LLC now owns 1,705,338 shares of the company’s stock worth $20,721,000 after acquiring an additional 1,684,072 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Eli Lilly and by 93.6% in the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock worth $250,681,000 after acquiring an additional 1,441,200 shares in the last quarter. Institutional investors own 75.72% of the company’s stock.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the transaction, the insider now owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 990,000 shares of company stock valued at $82,949,650 in the last three months. 0.20% of the stock is currently owned by corporate insiders.

LLY has been the subject of several recent research reports. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. Citigroup Inc. reiterated a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and in a research report on Tuesday, July 4th. Jefferies Group LLC reiterated a “buy” rating and issued a $93.00 price target on shares of Eli Lilly and in a research report on Thursday, June 22nd. Deutsche Bank AG reiterated a “buy” rating and issued a $91.00 price target (up previously from $90.00) on shares of Eli Lilly and in a research report on Monday, July 17th. Finally, Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a research report on Monday, July 17th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $88.42.

TRADEMARK VIOLATION WARNING: “National Planning Corp Raises Stake in Eli Lilly and Company (LLY)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/10/06/national-planning-corp-raises-stake-in-eli-lilly-and-company-lly.html.

Shares of Eli Lilly and Company (NYSE:LLY) opened at 87.65 on Friday. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $89.09. The stock’s 50 day moving average is $81.94 and its 200 day moving average is $82.12. The company has a market cap of $92.47 billion, a P/E ratio of 37.93 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter last year, the company posted $0.86 EPS. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. On average, analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.